Hormones and Sports: 2008 Olympics Special Section

Asian Journal of Andrology (2008) 10, 351–363; doi:10.1111/j.1745-7262.2008.00407.x

Hormones, Muscle and Performance

The physiological and pharmacological basis for the ergogenic effects of androgens in elite sports

Karen Choong, Kishore M Lakshman and Shalender Bhasin

Boston University School of Medicine, Section of Endocrinology, Diabetes, and Nutrition, Boston Medical Center, Boston, MA 02118, USA

Correspondence: Prof. Shalender Bhasin, Boston University School of Medicine, Section of Endocrinology, Diabetes, and Nutrition, Boston Medical Center, Boston, MA 02118, USA. Fax: +1-617-638-8217. E-mail: Shalender.Bhasin@bmc.org

Received 2 January 2008; Accepted 8 January 2008.

Top

Abstract

Androgen doping in power sports is undeniably rampant worldwide. There is strong evidence that androgen administration in men increases skeletal muscle mass, maximal voluntary strength and muscle power. However, we do not have good experimental evidence to support the presumption that androgen administration improves physical function or athletic performance. Androgens do not increase specific force or whole body endurance measures. The anabolic effects of testosterone on the skeletal muscle are mediated through androgen receptor signaling. Testosterone promotes myogenic differentiation of multipotent mesenchymal stem cells and inhibits their differentiation into the adipogenic lineage. Testosterone binding to androgen receptor induces a conformational change in androgen receptor protein, causing it to associate with beta-catenin and TCF-4 and activate downstream Wnt target genes thus promoting myogenic differentiation. The adverse effects of androgens among athletes and recreational bodybuilders are under reported and include acne, deleterious changes in the cardiovascular risk factors, including a marked decrease in plasma high-density lipoproteins (HDL) cholesterol level, suppression of spermatogenesis resulting in infertility, increase in liver enzymes, hepatic neoplasms, mood and behavioral disturbances, and long term suppression of the endogenous hypothalamic-pituitary-gonadal axis. Androgens are often used in combination with other drugs which may have serious adverse events of their own. In spite of effective methods for detecting androgen doping, the policies for screening of athletes are highly variable in different countries and organizations and even existing policies are not uniformly enforced.

Keywords:

testosterone, dihydrotestosterone, muscle mass, mechanisms of androgen action, androgen doping, mesenchymal stem cells, detection of androgen doping

Top

References

  1. Kahn A. Regaining lost youth: the controversial and colorful beginnings of hormone replacement therapy in aging. J Gerontol A Biol Sci Med Sci 2005; 60: 142–7. | PubMed |
  2. Freeman ER, Bloom DA, McGuire EJ. A brief history of testosterone. J Urol 2001; 165: 371–3. | Article | PubMed | ChemPort |
  3. Yesalis CE, Bahrke MS. Anabolic-androgenic steroids. Current issues. Sports Med 1995; 19: 326–40. | Article | PubMed | ChemPort |
  4. Brown-Sequard CE. The effects produced in man by subcutaneous injections of a liquid obtained from testicles of animals. Lancet 1889; 2: 105–7. | Article |
  5. Doping Boje O. Bulletin of Health Organization of the League of Nations. 1939; 8: 439–69.
  6. Wade N. Anabolic steroids: doctors denounce then but athletes aren't listening. Science 1972; 176: 1399–403. | Article | PubMed |
  7. Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol 2004; 4: 614–20. | Article | PubMed | ChemPort |
  8. Yesalis CE 3rd, Bahrke MS, Kopstein AN, Baruskiewicz CK. Incidence onabolic steroid use: a discussion of methodological issues. In: Yesalis CE 3rd, editor. Anabolic Steroids in Sports and Exercise. 2nd edn. Champaign: Human Kinetics; 2000, p 73–115.
  9. Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. JAMA 1993; 270: 1217–21. | Article | PubMed | ChemPort |
  10. Bahrke MS, Yesalis CE, Kopstein AN, Stephens JA. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med 2000; 29: 397–405. | Article | PubMed | ChemPort |
  11. Yesalis CE, Barsukiewicz CK, Kopstein AN, Bahrke MS. Trends in anabolic-androgenic steroid use among adolescents. Arch Pediatr Adolesc Med 1997; 151: 1197–206. | PubMed | ChemPort |
  12. Buckley WE, Yesalis CE 3rd, Friedl KE, Anderson WA, Streit AL, Wright JE. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA 1988; 260: 3441–5. | Article | PubMed | ChemPort |
  13. Irving LM, Wall M, Neumark-Sztainer D, Story M. Steroid use among adolescents: findings from project EAT. J Adolescent Health 2002; 30: 243–52. | Article |
  14. Melia P, Pipe A, Greenberg L. The use of anabolic-androgenic steroids by Canadian students. Clin J Sport Med 1996; 6: 9–14. | Article | PubMed | ChemPort |
  15. Handelsman DJ, Gupta L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian high school students. Int J Androl 1997; 20: 159–64. | Article | PubMed | ChemPort |
  16. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 1997; 43: 1262–79. | PubMed | ChemPort |
  17. McCabe SE, Brower KJ, West BT, Nelson TF, Wechsler H. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend 2007; 90: 243–51. | Article | PubMed |
  18. Mornitoring the Future. http://www.monitoringthefuture.org.
  19. Evans NA. Gym and tonic: a profile of 100 male steroid users. Br J Sports Med 1997; 31: 54–8. | Article | PubMed | ChemPort |
  20. Evans NA. Local complications of self administered anabolic steroid injections. Br J Sports Med 1997; 31: 349–50. | Article | PubMed | ChemPort |
  21. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry 1994; 51: 375–82. | PubMed | ChemPort |
  22. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1–7. | Article | PubMed | ISI | ChemPort |
  23. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281: E1172–81. | PubMed | ISI | ChemPort |
  24. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 2003; 88: 1478–85. | Article | PubMed | ISI | ChemPort |
  25. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006; 2: 146–59. | Article | PubMed | ChemPort |
  26. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995–2010. | Article | PubMed | ISI | ChemPort |
  27. Wilson JD. Androgen abuse by athletes. Endocr Rev 1988; 9: 181–99. | PubMed | ChemPort |
  28. Bhasin S, Woodhouse L, Storer TW. Proof of the effect of testosterone on skeletal muscle. J Endocrinol 2001; 170: 27–38. | Article | PubMed | ISI | ChemPort |
  29. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90: 678–88. | Article | PubMed | ISI | ChemPort |
  30. Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee M, Zerounian H, et al. Development of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab 2003; 284: E1009–17. | PubMed | ISI | ChemPort |
  31. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407–13. | Article | PubMed | ISI | ChemPort |
  32. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3469–75. | Article | PubMed | ISI | ChemPort |
  33. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670–7. | Article | PubMed | ISI | ChemPort |
  34. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85: 2839–53. | Article | PubMed | ISI | ChemPort |
  35. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358–65. | Article | PubMed | ISI | ChemPort |
  36. Baume N, Schumacher YO, Sottas PE, Bagutti C, Cauderay M, Mangin P, et al. Effect of multiple oral doses of androgenic anabolic steroids on endurance performance and serum indices of physical stress in healthy male subjects. Eur J Appl Physiol 2006; 98: 329–40. | Article | PubMed | ChemPort |
  37. Georgieva KN, Boyadjiev NP. Effects of nandrolone decanoate on VO2max, running economy, and endurance in rats. Med Sci Sports Exerc 2004; 36: 1336–41. | Article | PubMed | ChemPort |
  38. Hendler ED, Solomon LR. Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematol 1990; 83: 1–8. | PubMed | ChemPort |
  39. Blanco CE, Popper P, Micevych P. Anabolic-androgenic steroid induced alterations in choline acetyltransferase messenger RNA levels of spinal cord motoneurons in the male rat. Neuroscience 1997; 78: 873–82. | Article | PubMed | ChemPort |
  40. Blanco CE, Zhan WZ, Fang YH, Sieck GC. Exogenous testosterone treatment decreases diaphragm neuromuscular transmission failure in male rats. J Appl Physiol 2001; 90: 850–6. | PubMed | ChemPort |
  41. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 2002; 283: E154–64. | PubMed | ChemPort |
  42. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab 2003; 285: E197–205. | PubMed | ISI | ChemPort |
  43. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab 2004; 89: 5245–55. | Article | PubMed | ChemPort |
  44. Bhasin S, Taylor WE, Singh R, Artaza J, Sinha-Hikim I, Jasuja R, et al. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 2003; 58: M1103–10. | PubMed |
  45. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, et al. Testosterone inhibits adipogenic differentiation in 3T3–L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006; 147: 141–54. | Article | PubMed | ISI | ChemPort |
  46. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipo-genesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 5081–8. | Article | PubMed | ISI | ChemPort |
  47. Doumit ME, Cook DR, Merkel RA. Testosterone up-regulates androgen receptors and decreases differentiation of porcine myogenic satellite cells in vitro. Endocrinology 1996; 137: 1385–94. | Article | PubMed | ChemPort |
  48. Joubert Y, Tobin C. Satellite cell proliferation and increase in the number of myonuclei induced by testosterone in the levator ani muscle of the adult female rat. Dev Biol 1989; 131: 550–7. | Article | PubMed | ChemPort |
  49. Joubert Y, Tobin C. Testosterone treatment results in quiescent satellite cells being activated and recruited into cell cycle in rat levator ani muscle. Dev Biol 1995; 169: 286–94. | Article | PubMed | ChemPort |
  50. Mulvaney DR, Marple DN, Merkel RA. Proliferation of skeletal muscle satellite cells after castration and administration of testosterone propionate. Proc Soc Exp Biol Med 1988; 188: 40–5. | PubMed | ChemPort |
  51. Nnodim JO. Testosterone mediates satellite cell activation in denervated rat levator ani muscle. Anat Rec 2001; 263: 19–24. | Article | PubMed | ChemPort |
  52. Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ. Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab 2003; 88: 358–62. | Article | PubMed | ISI | ChemPort |
  53. Ferrando AA, Sheffield-Moore M, Wolf SE, Herndon DN, Wolfe RR. Testosterone administration in severe burns ameliorates muscle catabolism. Crit Care Med 2001; 29: 1936–42. | Article | PubMed | ChemPort |
  54. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002; 282: E601–7. | PubMed | ISI | ChemPort |
  55. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 1991; 151: 1925–33. | Article | PubMed | ChemPort |
  56. Ansell JE, Tiarks C, Fairchild VK. Coagulation abnormalities associated with the use of anabolic steroids. Am Heart J 1993; 125: 367–71. | Article | PubMed | ChemPort |
  57. Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992; 12: 73–9. | PubMed | ChemPort |
  58. Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, McConathy WJ. Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med 1999; 9: 34–9. | Article | PubMed | ChemPort |
  59. Pertusi R, Dickerman RD, McConathy WJ. Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: hepatitis or rhabdomyolysis? J Am Osteopath Assoc 2001; 101: 391–4. | PubMed | ChemPort |
  60. Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 2005; 39: e27. | Article | PubMed | ChemPort |
  61. Bonetti A, Tirelli F, Catapano A, Dazzi D, Dei Cas A, Solito F, et al. Side effects of anabolic androgenic steroids abuse. Int J Sports Med 2007; Nov 14 [Epub ahead of print].
  62. Bahrke MS, Yesalis CE 3rd, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update. Sports Med 1996; 22: 367–90. | Article | PubMed | ChemPort |
  63. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993; 269: 2760–4. | Article | PubMed | ISI | ChemPort |
  64. Patil JJ, O'Donohoe B, Loyden CF, Shanahan D. Near-fatal spontaneous hepatic rupture associated with anabolic androgenic steroid use: a case report. Br J Sports Med 2007; 41: 462–3. | Article | PubMed | ChemPort |
  65. Calof O, Singh AB, Lee ML, Urban RJ, Kenny AM, Tenover JL, et al. Adverse events associated with testosterone supplementation of older men. J Greontol Med Sci 2006; 2: 146–59.
  66. Wight JN Jr, Salem D. Sudden cardiac death and the "athlete's heart". Arch Intern Med 1995; 155: 1473–80. | Article | PubMed |
  67. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 1995; 27: 1252–62. | PubMed | ChemPort |
  68. Karila TA, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppala TA. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 2003; 24: 337–43. | Article | PubMed | ChemPort |
  69. Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000; 21: 225–7. | Article | PubMed | ChemPort |
  70. Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 1987; 64: 960–3. | PubMed | ChemPort |
  71. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 1998; 41: 1–15. | Article | PubMed | ChemPort |
  72. Lenders JW, Demacker PN, Vos JA, Jansen PL, Hoitsma AJ, van't Laar A, et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int J Sports Med 1988; 9: 19–23. | Article | PubMed | ChemPort |
  73. De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E. Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. Int J Sports Med 1991; 12: 408–12. | Article | PubMed | ChemPort |
  74. Dickerman RD, Schaller F, Zachariah NY, McConathy WJ. Left ventricular size and function in elite bodybuilders using anabolic steroids. Clin J Sport Med 1997; 7: 90–3. | Article | PubMed | ChemPort |
  75. Salke RC, Rowland TW, Burke EJ. Left ventricular size and function in body builders using anabolic steroids. Med Sci Sports Exerc 1985; 17: 701–4. | Article | PubMed | ChemPort |
  76. Zuliani U, Bernardini B, Catapano A, Campana M, Cerioli G, Spattini M. Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameters in body builders. Int J Sports Med 1989; 10: 62–6. | Article | PubMed | ChemPort |
  77. Pearson AC, Schiff M, Mrosek D, Labovitz AJ, Williams GA. Left ventricular diastolic function in weight lifters. Am J Cardiol 1986; 58: 1254–9. | Article | PubMed | ChemPort |
  78. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart 2004; 90: 496–501. | Article | PubMed | ChemPort |
  79. Graham MR, Grace FM, Boobier W, Hullin D, Kicman A, Cowan D, et al. Homocysteine induced cardiovascular events: a consequence of long term anabolic-androgenic steroid (AAS) abuse. Br J Sports Med 2006; 40: 644–8. | Article | PubMed | ChemPort |
  80. Nieminen MS, Ramo MP, Viitasalo M, Heikkila P, Karjalainen J, Mantysaari M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1996; 17: 1576–83. | PubMed | ChemPort |
  81. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart 2004; 90: 473–5. | Article | PubMed | ChemPort |
  82. D'Andrea A, Caso P, Salerno G, Scarafile R, De Corato G, Mita C, et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br J Sports Med 2007; 41: 149–55. | Article | PubMed |
  83. Chung T, Kelleher S, Liu PY, Conway AJ, Kritharides L, Handelsman DJ. Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study. Clin Endocrinol (Oxf) 2007; 66: 235–45. | Article | PubMed | ChemPort |
  84. Hartgens F, Cheriex EC, Kuipers H. Prospective echocardio-graphic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 2003; 24: 344–51. | Article | PubMed | ChemPort |
  85. Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, et al. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men—a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3754–8. | Article | PubMed | ISI | ChemPort |
  86. Daly RC, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendo-crinology 2003; 28: 317–31. | Article | ChemPort |
  87. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. Biol Psychiatry 1999; 45: 254–60. | Article | PubMed | ChemPort |
  88. Kouri EM, Lukas SE, Pope HG Jr, Oliva PS. Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend 1995; 40: 73–9. | Article | PubMed | ChemPort |
  89. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 2000; 57: 133–40. | Article | PubMed | ISI | ChemPort |
  90. Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 1992; 75: 1503–7. | Article | PubMed | ISI | ChemPort |
  91. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur Psychiatry 2006; 21: 551–62. | Article | PubMed |
  92. Gill GV. Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin. Postgrad Med J 1998; 74: 45–6. | PubMed | ChemPort |
  93. MacIndoe JH, Perry PJ, Yates WR, Holman TL, Ellingrod VL, Scott SD. Testosterone suppression of the HPT axis. J Investig Med 1997; 45: 441–7. | PubMed | ChemPort |
  94. Lloyd FH, Powell P, Murdoch AP. Anabolic steroid abuse by body builders and male subfertility. BMJ 1996; 313: 100–1. | PubMed | ChemPort |
  95. Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med 1990; 18: 429–31. | Article | PubMed | ChemPort |
  96. Brower KJ. Anabolic steroid abuse and dependence. Curr Psychiatry Rep 2002; 4: 377–87. | Article | PubMed |
  97. Brower KJ, Blow FC, Young JP, Hill EM. Symptoms and correlates of anabolic-androgenic steroid dependence. Br J Addict 1991; 86: 759–68. | Article | PubMed | ChemPort |
  98. Brower KJ, Eliopulos GA, Blow FC, Catlin DH, Beresford TP. Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters. Am J Psychiatry 1990; 147: 510–2. | PubMed | ChemPort |
  99. Evans NA, Bowrey DJ, Newman GR. Ultrastructural analysis of ruptured tendon from anabolic steroid users. Injury 1998; 29: 769–73. | Article | PubMed | ChemPort |
  100. Schanzer W. Metabolism of anabolic androgenic steroids. Clin Chem 1996; 42: 1001–20. | PubMed | ChemPort |
  101. Schanzer W. Abuse of androgens and detection of illegal use. In: Nieschlag E, Behre HM, editors Testosterone: Action, Deficiency, Substitution. 3rd edn. Cambridge: Cambridge University Press; 2004. p 715–36.
  102. Aguilera R, Becchi M, Grenot C, Casabianca H, Hatton CK. Detection of testosterone misuse: comparison of two chromatographic sample preparation methods for gas chromatographic-combustion/isotope ratio mass spectrometric analysis. J Chromatogr B Biomed Appl 1996; 687: 43–53. | Article | PubMed | ChemPort |
  103. Aguilera R, Chapman TE, Starcevic B, Hatton CK, Catlin DH. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. Clin Chem 2001; 47: 292–300. | PubMed | ChemPort |
  104. Catlin DH, Hatton CK, Starcevic SH. ssues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Clin Chem 1997; I 43: 1280–8.
  105. Garle M, Ocka R, Palonek E, Bjorkhem I. Increased urinary testosterone/epitestosterone ratios found in Swedish athletes in connection with a national control program. Evaluation of 28 cases. J Chromatogr B Biomed Appl 1996; 687: 55–9. | Article | PubMed | ChemPort |
  106. Gonzalo-Lumbreras R, Pimentel-Trapero D, Izquierdo-Hornillos R. Development and method validation for testosterone and epitestosterone in human urine samples by liquid chromatography applications. J Chromatogr Sci 2003; 41: 261–5. | PubMed | ChemPort |
  107. Hebestreit M, Flenker U, Buisson C, Andre F, Le Bizec B, Fry H, et al. Application of stable carbon isotope analysis to the detection of testosterone administration to cattle. J Agric Food Chem 2006; 54: 2850–8. | Article | PubMed | ChemPort |
  108. Saudan C, Baume N, Robinson N, Avois L, Mangin P, Saugy M. Testosterone and doping control. Br J Sports Med 2006; 40 (Suppl 1): i21–4. | Article | PubMed |
  109. Sottas PE, Baume N, Saudan C, Schweizer C, Kamber M, Saugy M. Bayesian detection of abnormal values in longitudinal biomarkers with an application to T/E ratio. Biostatistics 2007; 8: 285–96. | Article | PubMed |
  110. Shackleton CH, Phillips A, Chang T, Li Y. Confirming testosterone administration by isotope ratio mass spectrometric analysis of urinary androstanediols. Steroids 1997; 62: 379–87. | Article | PubMed | ChemPort |
  111. Le Bizec B, Gaudin I, Monteau F, Andre F, Impens S, De Wasch K, et al. Consequence of boar edible tissue consumption on urinary profiles of nandrolone metabolites. I. Mass spectrometric detection and quantification of 19-norandrosterone and 19-noretiocholanolone in human urine. Rapid Commun Mass Spectrom 2000; 14: 1058–65. | Article | PubMed | ChemPort |
  112. Catlin DH, Leder BZ, Ahrens B, Starcevic B, Hatton CK, Green GA, et al. Trace contamination of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite. JAMA 2000; 284: 2618–21. | Article | PubMed | ISI | ChemPort |
  113. Kottke MK. Scientific and regulatory aspects of nutraceutical products in the United States. Drug Dev Ind Pharm 1998; 24: 1177–95. | Article | PubMed | ChemPort |
  114. Stevens K. Dietary Supplement Health and Education Act: quiet but far-reaching consequences. Altern Ther Health Med 1995; 1: 17–8. | PubMed | ChemPort |
  115. Jasuja R, Ramaraj P, Mac RP, Singh AB, Storer TW, Artaza J, et al. Delta-4-androstene-3,17-dione binds androgen receptor, promotes myogenesis in vitro, and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men. J Clin Endocrinol Metab 2005; 90: 855–63. | Article | PubMed | ChemPort |
  116. Leder BZ, Leblanc KM, Longcope C, Lee H, Catlin DH, Finkelstein JS. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 5449–54. | Article | PubMed | ChemPort |
  117. Glickman SE, Coscia EM, Frank LG, Licht P, Weldele ML, Drea CM. Androgens and masculinization of genitalia in the spotted hyaena (Crocuta crocuta). 3. Effects of juvenile gonadectomy. J Reprod Fertil 1998; 113: 129–35. | PubMed | ChemPort |
  118. Leder BZ, Longcope C, Catlin DH, Ahrens B, Schoenfeld DA, Finkelstein JS. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 2000; 283: 779–82. | Article | PubMed | ChemPort |
  119. Brown GA, Vukovich MD, Martini ER, Kohut ML, Franke WD, Jackson DA, et al. Endocrine responses to chronic androstenedione intake in 30-to 56-year-old men. J Clin Endocrinol Metab 2000; 85: 4074–80. | Article | PubMed | ChemPort |
  120. Brown GA, Vukovich MD, Martini ER, Kohut ML, Franke WD, Jackson DA, et al. Effects of androstenedione-herbal supplementation on serum sex hormone concentrations in 30- to 59-year-old men. Int J Vitam Nutr Res 2001; 71: 293–301. | Article | PubMed | ChemPort |
  121. King DS, Sharp RL, Vukovich MD, Brown GA, Reifenrath TA, Uhl NL, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA 1999; 281: 2020–8. | Article | PubMed | ChemPort |
  122. Leder BZ, Catlin DH, Longcope C, Ahrens B, Schoenfeld DA, Finkelstein JS. Metabolism of orally administered androstenedione in young men. J Clin Endocrinol Metab 2001; 86: 3654–8. | Article | PubMed | ChemPort |
  123. Delbeke FT, Van Eenoo P, Van Thuyne W, Desmet N. Prohormones and sport. J Steroid Biochem Mol Biol 2002; 83: 245–51. | Article | PubMed | ChemPort |
  124. van der Merwe PJ, Grobbelaar E. Unintentional doping through the use of contaminated nutritional supplements. S Afr Med J 2005; 95: 510–1. | PubMed | ChemPort |
  125. Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Schanzer W. Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids - results of an international study. Int J Sports Med 2004; 25: 124–9. | Article | PubMed | ISI | ChemPort |
  126. Baulieu EE, Robel P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc Natl Acad Sci U S A 1998; 95: 4089–91. | Article | PubMed | ChemPort |
  127. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 2002; 277: 21379–88. | Article | PubMed | ISI | ChemPort |
  128. Demirgoren S, Majewska MD, Spivak CE, London ED. Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor. Neuro-science 1991; 45: 127–35. | ChemPort |
  129. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341: 1013–20. | Article | PubMed | ISI | ChemPort |
  130. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000; 85: 4650–6. | Article | PubMed | ChemPort |
  131. Lovas K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebo BG, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9–month, randomized, parallel group clinical trial. J Clin Endocrinol Metab 2003; 88: 1112–8. | Article | PubMed | ChemPort |
  132. Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 2046–52. | Article | PubMed | ChemPort |
  133. Gebre-Medhin G, Husebye ES, Mallmin H, Helstrom L, Berne C, Karlsson FA, et al. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clin Endocrinol (Oxf) 2000; 52: 775–80. | Article | PubMed | ChemPort |
  134. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998; 49: 421–32. | Article | PubMed | ChemPort |
  135. Arlt W, Callies F, Koehler I, van Vlijmen JC, Fassnacht M, Strasburger CJ, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 2001; 86: 4686–92. | Article | PubMed | ChemPort |
  136. Callies F, Arlt W, Siekmann L, Hubler D, Bidlingmaier F, Allolio B. Influence of oral dehydroepiandrosterone (DHEA) on urinary steroid metabolites in males and females. Steroids 2000; 65: 98–102. | Article | PubMed | ChemPort |
  137. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999; 156: 646–9. | PubMed | ChemPort |
  138. Huppert FA, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane review. In: Cochrane Library. Chichester, UK: John Wiley and Sons Ltd., 2003. CD000304.
  139. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999; 84: 1527–33. | Article | PubMed | ChemPort |
  140. Genazzani AD, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani AR. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 2003; 80: 1495–501. | Article | PubMed |
  141. Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999; 84: 3896–902. | Article | PubMed | ChemPort |
  142. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 2924–7. | Article | PubMed | ISI | ChemPort |
  143. Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3591–5. | Article | PubMed | ChemPort |
  144. van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepi-androsterone in severe systemic lupus erythematosus. Lupus 1999; 8: 181–7. | Article | PubMed | ChemPort |
  145. Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 2006; 91: 2986–93. | Article | PubMed | ISI | ChemPort |
  146. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang YC, Hatton CK. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Mass Spectrom 2004; 18: 1245–9. | Article | PubMed | ChemPort |
  147. Jasuja R, Catlin DH, Miller A, Chang YC, Herbst KL, Starcevic B, et al. Tetrahydrogestrinone is an androgenic steroid that stimulates androgen receptor-mediated, myogenic differentiation in C3H10T1/2 multipotent mesenchymal cells and promotes muscle accretion in orchidectomized male rats. Endocrinology 2005; 146: 4472–8. | Article | PubMed | ChemPort |
  148. Sekera MH, Ahrens BD, Chang YC, Starcevic B, Georgakopoulos C, Catlin DH. Another designer steroid: discovery, synthesis, and detection of 'madol' in urine. Rapid Commun Mass Spectrom 2005; 19: 781–4. | Article | PubMed | ChemPort |
  149. Handelsman DJ. Designer androgens in sport: when too much is never enough. Sci STKE 2004: pe 41.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

RESEARCH

The physiological and pharmacological basis for the ergogenic effects of androgens in elite sports

Asian Journal of Andrology Original Article

Androgenic-anabolic steroids and the Olympic Games

Asian Journal of Andrology Original Article

Androgenic-anabolic steroids and the Olympic Games

Asian Journal of Andrology Original Article

Androgen abuse in sports

Asian Journal of Andrology Original Article

See all 11 matches for Research

Extra navigation

.

naturejobs

More science jobs
Post a job for free
ADVERTISEMENT